Academic Journals Database
Disseminating quality controlled scientific knowledge

Digitoxin and its analogs as novel cancer therapeutics

ADD TO MY LIST
 
Author(s): Elbaz Hosam A | Stueckle Todd A | Tse William | Rojanasakul Yon | Dinu Cerasela

Journal: Experimental Hematology & Oncology
ISSN 2162-3619

Volume: 1;
Issue: 1;
Start page: 4;
Date: 2012;
Original page

ABSTRACT
Abstract A growing body of evidence indicates that digitoxin cardiac glycoside is a promising anticancer agent when used at therapeutic concentrations. Digitoxin has a prolonged half-life and a well-established clinical profile. New scientific avenues have shown that manipulating the chemical structure of the saccharide moiety of digitoxin leads to synthetic analogs with increased cytotoxic activity. However, the anticancer mechanism of digitoxin or synthetic analogs is still subject to study while concerns about digitoxin's cardiotoxicity preclude its clinical application in cancer therapeutics. This review focuses on digitoxin and its analogs, and their cytotoxicity against cancer cells. Moreover, a new perspective on the pharmacological aspects of digitoxin and its analogs is provided to emphasize new research directions for developing potent chemotherapeutic drugs.
Why do you need a reservation system?      Affiliate Program